Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.